Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share
-
Shares outstanding
-
266,212,950
-
Total 13F shares
-
109,330,876
-
Share change
-
+5,028,811
-
Total reported value
-
$260,181,467
-
Put/Call ratio
-
6.3%
-
Price per share
-
$2.38
-
Number of holders
-
67
-
Value change
-
+$12,434,850
-
Number of buys
-
30
-
Number of sells
-
24
Institutional Holders of Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) as of Q2 2023
As of 30 Jun 2023,
Autolus Therapeutics plc - Ordinary Shares, nominal value $0.000042 per share, and American Depositary Shares ("ADS"). Each ADS represents one Ordinary Share (AUTL) was held by
67 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
109,330,876 shares.
The largest 10 holders included
Syncona Portfolio Ltd, Blackstone Inc., Deep Track Capital, LP, TFG Asset Management GP Ltd, Paradigm Biocapital Advisors LP, ARMISTICE CAPITAL, LLC, Nantahala Capital Management, LLC, Frazier Life Sciences Management, L.P., Perpetual Ltd, and SCHRODER INVESTMENT MANAGEMENT GROUP.
This page lists
67
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.